19 Article(s)Download |
PMID | Title | Pub. Year | #Total Relationships |
1 | 35126712 | Harmine reinforces the effects of regorafenib on suppressing cell proliferation and inducing apoptosis in liver cancer cells. | 2022 Mar | 6 |
2 | 35244188 | DYRK1A suppression attenuates HIF‑1α accumulation and enhances the anti‑liver cancer effects of regorafenib and sorafenib under hypoxic conditions. | 2022 Apr | 1 |
3 | 35502476 | Regorafenib induces the apoptosis of gastrointestinal cancer-associated fibroblasts by inhibiting AKT phosphorylation. | 2022 May 2 | 3 |
4 | 34596810 | Catalpol synergistically potentiates the anti-tumour effects of regorafenib against hepatocellular carcinoma via dual inhibition of PI3K/Akt/mTOR/NF-κB and VEGF/VEGFR2 signaling pathways. | 2021 Nov | 3 |
5 | 32457362 | Regorafenib is effective against neuroblastoma in vitro and in vivo and inhibits the RAS/MAPK, PI3K/Akt/mTOR and Fos/Jun pathways. | 2020 Aug | 2 |
6 | 30929918 | Suppression of LSD1 enhances the cytotoxic and apoptotic effects of regorafenib in hepatocellular carcinoma cells. | 2019 May 14 | 1 |
7 | 31163381 | Apoptosis induction and AKT/NF-κB inactivation are associated with regroafenib-inhibited tumor progression in non-small cell lung cancer in vitro and in vivo. | 2019 Aug | 2 |
8 | 31238539 | Protein Kinase B and Extracellular Signal-Regulated Kinase Inactivation is Associated with Regorafenib-Induced Inhibition of Osteosarcoma Progression In Vitro and In Vivo. | 2019 Jun 24 | 2 |
9 | 31501414 | A positive feedback loop of β-catenin/CCR2 axis promotes regorafenib resistance in colorectal cancer. | 2019 Sep 9 | 1 |
10 | 29359239 | The orally available multikinase inhibitor regorafenib (BAY 73-4506) in multiple myeloma. | 2018 May | 1 |
11 | 29609689 | Regorafenib delays the proliferation of hepatocellular carcinoma by inducing autophagy. | 2018 Apr 2 | 1 |
12 | 29783729 | Chlorogenic Acid Improves the Regorafenib Effects in Human Hepatocellular Carcinoma Cells. | 2018 May 19 | 2 |
13 | 28000898 | Regorafenib induces extrinsic and intrinsic apoptosis through inhibition of ERK/NF-κB activation in hepatocellular carcinoma cells. | 2017 Feb | 1 |
14 | 28166200 | Upregulation of MARCKS in kidney cancer and its potential as a therapeutic target. | 2017 Jun 22 | 1 |
15 | 28978118 | Regorafenib in combination with silybin as a novel potential strategy for the treatment of metastatic colorectal cancer. | 2017 Sep 15 | 1 |
16 | 26419617 | Involvement of Notch-1 in Resistance to Regorafenib in Colon Cancer Cells. | 2016 May | 1 |
17 | 25838391 | Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab. | 2015 Jul 1 | 1 |
18 | 25132955 | Characterization and assessment of the sensitivity and resistance of a newly established human gastrointestinal stromal tumour xenograft model to treatment with tyrosine kinase inhibitors. | 2014 | 1 |
19 | 23877009 | Sorafenib/regorafenib and phosphatidyl inositol 3 kinase/thymoma viral proto-oncogene inhibition interact to kill tumor cells. | 2013 Oct | 1 |